ReviewTransfusion medicine (Oxford, England)2026
Immune-mediated platelet refractoriness: Mechanisms, diagnostics, and therapeutic breakthroughs.
Review in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Platelets are increasingly recognised as key mediators of immunity, contributing to clinical challenges such as platelet transfusion refractoriness (PTR). While predominantly driven by non-immune factors, immune-mediated PTR-primarily due to alloimmunisation against human leukocyte antigens (HLA) and/or human platelet antigens (HPA)-presents distinct management difficulties. Current therapies are often suboptimal, and emerging strategies require validation. This review synthesises current knowledge on antibody pathogenesis, advanced detection methods, and novel therapies for immune-mediated PTR, aiming to inform clinical decision-making and future research. A comprehensive literature review was conducted, focusing on peer-reviewed articles addressing immune-mediated PTR, mechanisms of alloimmunisation, diagnostic techniques for HLA/HPA antibodies, and therapeutic innovations. Key studies and emerging data were analysed to evaluate current evidence and identify knowledge gaps. Immune-mediated PTR arises primarily from alloantibodies against HLA class I and/or HPA, leading to accelerated platelet clearance. Advanced detection methods, including multiplex bead arrays and genotyping platforms, have improved identification of incompatible donors. Current management relies on provision of antigen-negative or crossmatch-compatible platelets, with immunosuppressive therapy reserved for refractory cases. Novel strategies such as platelet genome editing, antibody inhibition, and nanoparticle-based immune modulation are under investigation, but robust clinical validation is lacking. This review highlights the central role of alloimmunisation in immune-mediated PTR and the importance of accurate antibody detection and antigen matching. While existing therapies remain suboptimal for some patients, emerging technologies hold potential but require further clinical evaluation. Improved understanding of pathogenesis and validation of novel approaches are essential to advance management and reduce the burden of PTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.